Within two months of its launch, ChatGPT had already registered 100 million users—setting a record for the fastest-growing base of users. Such strong adoption underscores the potential that people in many industries see in generative AI. For medtech companies, the technology can make processes more efficient, help companies personalize customer interactions, unlock innovation through unconventional creativity, and better access enterprise data and knowledge to create value in new ways.
The main challenge is knowing how and where to start. Because generative AI has such a broad set of potential applications, and because medtech is a highly regulated industry where people’s lives are at stake, some companies may adopt a wait-and-see approach. We believe such inaction would risk putting companies at a long-term disadvantage. Generative AI is projected to grow faster in health care than any other industry, with a compound annual growth rate of 85% through 2027, to reach a total market size of $22 billion. (See Exhibit 1.)
For that reason, medtech companies should begin implementing the technology in various parts of their business. We identified more than 60 use cases for generative AI across the entire medtech value chain, and ranked them based on their impact and speed of implementation to identify the biggest near-term opportunities. The common theme? All have strong potential to help medtech companies work smarter and faster—and ultimately create value for the companies ambitious enough to apply them.
Traditional AI sifts through historical data to identify patterns and insights. Generative AI goes beyond that. It still entails models built on vast quantities of data, but it uses that information to generate new content such as text, media (video, images, speech), computer-aided design, and software code. For medtech companies, the main advantages of generative AI are as follows:
In the short term, companies can adopt commercially available generative AI offerings (such as GitHub Copilot X or Jasper), or fine-tune existing generative AI models. Over the long term, companies can unlock greater value by developing more advanced use cases that entail more comprehensive changes to internal processes along the value chain—and ultimately develop novel products and services that are built on generative AI technologies.
We have developed a repository of more than 60 use cases across the entire value chain as a starting point for exploration. (See Exhibit 2.) Critically, we also ranked these in terms of their impact for medtech firms and speed of implementation, enabling companies to focus on those that could deliver quick wins and thus build up organizational capabilities and confidence. Exhibit 3 shows the 15 use cases with particularly high value based on this prioritization.
Generative AI models can support software development, an area where medtech companies often struggle with high costs (in some product segments, more than 50% of total product development costs) and insufficient talent. Generative AI solutions can address both challenges. For example, GitHub Copilot X is a generative model trained on billions of lines of code that can transform natural language input into code suggestions, saving programmers substantial time. Initial pilots suggest that tasks can be completed up to 55% faster. In addition, generative AI solutions can create test cases, document code, and automate code reviews (offered by companies such as Mintlify and Amazon CodeWhisperer).
Beyond software, generative AI can apply unconventional creativity to help companies discover new product designs (using generative design tools offered by companies like PTC, nTop, or Autodesk). Further value can come through streamlining the time-consuming process of converting internal documents into regulatory submissions—often hundreds of pages long—or clinical trial reports. Several startups are working on regulatory solutions, though none are commercially available yet.
One of the more noteworthy aspects of generative AI is that it can enable AI applications even with insufficient training data. For example, in a novel process that doesn’t have significant data, the tool can extrapolate from limited information by creating synthetic data that can then be used to train machine learning models. In medtech operations, this approach can improve quality in production processes by identifying flawed products much faster, rather than waiting for the errors to occur in real-world situations. Quality systems trained with synthetic data can detect product flaws from day one, using computer vision or other sensors and automatically removing faulty products from the production line (for example, via robotic bin-picking).
Generative AI can further enhance procurement processes by simplifying access to the broad base of supplier data ranging from existing contracts or proposals to public information on the supplier or industry (for example, financial data, news, and trends). Through advanced natural language comprehension, algorithms can summarize information as well as identify potential risks, thus enabling procurement teams to make informed decisions.
In the past few years, medtech sales teams have faced increasingly tighter restrictions on in-person visits to their customers. As a result, many have invested in digital sales capabilities. Generative AI can turbocharge those efforts, enabling mass personalization and tailoring marketing messages to resonate more effectively with different customer segments—and thus increase conversion rates.
Specifically, generative AI can consolidate information from a wide array of sources, both internal (client visit reports using customer relationship management programs) and external (media coverage, company website) to generate account-specific insights. It can guide sales reps to the next-best action for a given customer and prepare bespoke content to support that action. During and after a sales interaction, Generative AI solutions can automatically document the visit, capturing and analyzing customer information to generate insights that support the next interaction. Key CRM vendors are starting to offer initial versions of this kind of functionality, including Salesforce’s Einstein GPT, HubSpot’s Chatspot.ai, and Microsoft’s Viva Sales Copilot.
Across medtech companies, customer support is a highly manual and time-consuming task. Generative AI can substantially reduce the manual effort required in areas like order management and other administrative requests. Because it can interact with customers and has all the necessary information at hand, it can offer better customer service without staff involvement, providing real-time details on product availability, delivery timing, and other information.
Looking at specific support for individual products or services, fine-tuned voice or chatbots can incorporate information such as past service tickets and product manuals to provide trouble-shooting suggestions to customers, determine the right supporting documentation or assets from a library, and escalate more complex requests to human agents—all with greater sophistication and service levels compared with current offerings. Potential vendors in this area include Forethought and Zendesk.
Going beyond that, future solutions can use generative AI to analyze customer and product usage data to assess whether customers are capitalizing on the full range of features—or consistently hitting problem spots in a given process. Generative AI can also use advanced language comprehension to engage with customers in a conversation to improve customer success. These solutions can also integrate with sales functions to identify cross-selling and upselling opportunities.
Independent of specific steps in the medtech value chain, generative AI can make productivity and collaboration tools more efficient. This applies both to out-of-the-box office applications (such as Microsoft 365 Copilot or Google Workspace) and to customized applications—such as using a generative AI model to respond to company-specific internal questions. For example, Morgan Stanley is testing an OpenAI-powered chatbot trained on a vast amount of internal and external broker reports to support its financial advisors.
Generative AI is also expected to streamline the creation of custom reports and analyses, by converting natural language into machine requests. This would make data more easily accessible and generate actionable insights for business leaders in near real-time.
In HR, generative AI can help companies identify suitable candidates for jobs and draft individualized messages to improve engagement (using tools such as hireEZ). Initial clarifying questions or even prescreenings can be handled autonomously, with the system screening candidates and presenting a subset of finalists for a hiring manager to interview.
In addition to the benefits along the value chain as cited in the use cases, generative AI can fundamentally shape how medical services are provided. For example, it can:
Incorporating generative AI into products and services more comprehensively will require resolving questions around regulatory processes—particularly in Europe, which is behind the US in terms of providing regulatory clarity about the use of AI in medtech devices. Nevertheless, companies can look ahead and think about how their products can change and use generative AI to interact with patients in new ways. This is especially true for medical software businesses.
Given the potential impact from generative AI, medtech companies need to act. In contrast to other emerging technologies, gains in efficiency and effectiveness can come quickly. Therefore, we recommend three steps.
First, companies need to identify the specific use cases of generative AI that hold the most potential for their offerings of products and services. This entails quantifying their impact and speed of implementation, factoring in elements such as the availability of models and data, error tolerance, data security, affordability, and market demand.
Based on our discussions with several medtech companies and functional experts, we believe the following use cases have significant short-term potential along the value chain:
Generative AI use cases to accelerate software development and improve customer support bots are novel today. But they will become table stakes as more companies adopt them. Companies need a clear perspective for where they can derive the largest competitive advantage by integrating generative AI into medtech products and services or value chain activities. As an initial step, organizations could review the impact of generative AI on their existing product and service portfolio (where it could be improved) and review their client/patient flows (where new offerings could be added). Note that value chain activities and operating models might change substantially, and companies should be clear about where the largest value potential lies for them.
Once use cases have proven their impact, it’s essential to scale them up across the organization to capture their full value in terms of policies and talent.
Generative AI provides clear opportunities for medtech companies to optimize internal processes and later disrupt the market through new products and services. For that reason, medtech leaders must seize the initiative by identifying and piloting high-value use cases; considering strategic implications of the technology; and preparing people and policies to enable the change.
The authors would like to thank Dominik Parak and Michael Nuebler who contributed to this article.
To realize the promise and potential for GenAI, medtech executives must make swift and targeted efforts.
Rather than focusing on discrete products, companies should develop platforms based on modular designs, with hardware and software that can be continuously upgraded.
Experts across BCG and BCG X talk about the trends and opportunities that lie ahead for the digital health care market.
Medical technology companies play a big part in health care’s carbon emissions problem, both at the patient and provider levels. Fortunately, these firms can reduce their footprint affordably.
Here’s what to keep in mind when developing and commercializing software as a medical device.
A sea change is underway in how companies win regulatory approval for new health care products—particularly in the use of digital technology—and which markets they prioritize.
